semaglutide lilly Ozempic maker slumps further in fight with Eli Lilly, Zepbound Eli Lilly and Novo Nordisk
Description
Two pillars met (clinical protocol, follow-up cadence)
This raises questions about ways to possibly prioritize access to these treatments for diabetics and whether government agencies and payers could do more to address this problem
GLP-1 therapy is typically a long-term commitment
While its true that some individuals experience weight regain after coming off GLP-1 therapy, its not inevitable
In STEP 1 it produced about 15% body-weight loss over 68 weeks, with roughly a third of users reaching 20% or more
How does testing work
